CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2019—The FDA approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first noninsulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
The efficacy and safety of Victoza (Novo Nordisk) for reducing blood sugar in patients with type 2 diabetes was studied in several placebo-controlled trials in adults and one placebo-controlled trial with 134 pediatric patients 10 years and older for more than 26 weeks. Approximately 64 percent of patients in the pediatric study had a reduction in their hemoglobin A1c below seven percent while on Victoza, compared with 37 percent who achieved these results with the placebo.